688139 海尔生物
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,223,285-3.71%2,280,8962,864,0452,125,8631,402,029
减:营业总成本979,179-5.39%1,966,9372,293,3961,688,3161,082,247
    其中:营业成本632,770-0.56%1,125,9781,484,8811,059,842694,110
               财务费用(28,270)165.97%(23,532)(20,279)(11,883)(14,367)
               资产减值损失(1,729)13.67%(1,643)(5,410)(1,328)(1,360)
公允价值变动收益(1,139)-178.04%2,056(7,007)10,2083,831
投资收益11,307-80.55%83,03374,721473,26789,962
    其中:对联营企业和合营企业的投资收益2,88139.48%8,1738,96314,19326,828
营业利润256,790-17.70%438,401675,680961,434427,548
利润总额258,869-15.75%434,491675,336960,871424,236
减:所得税费用19,732-14.41%22,43363,362111,70140,112
净利润239,137-15.86%412,059611,974849,170384,123
减:非控股权益4,794-16.60%5,98511,1834,1353,169
股东净利润234,343-15.84%406,074600,791845,035380,954

市场价值指针
每股收益 (元) *0.740-15.91%1.2801.8902.6701.200
每股派息 (元) *----0.5150.4500.5000.380
每股净资产 (元) *13.3803.06%13.30612.64511.4268.755
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容